Mina and Sledge presented a valuable overview of the changes that have occurred during the past few decades in the treatment of breast cancer. I am pleased to be invited to offer my personal observations on the changes that have occurred in the endocrine treatment of breast cancer over this period. These changes are considerable, and I will approach my task as an observer from the bottom looking up. I say this because, as a new PhD graduate in pharmacology who had studied "antiestrogens" as an academic exercise from 1969 to 1972, I was told I could now do anything I wanted. I chose to contribute to the reinvention of an orphan drug, ICI 46,474, into tamoxifen.
Each generation creates and defends its own fashion in cancer research, and this concept is well illustrated by the early resistance to change in the approach to treating breast cancer. Virtually no one was interested in "another endocrine therapy," as combination cyto-toxic chemotherapy was predicted to cure cancer.
In contrast, it is now clear that the approach to health care has changed in the past 20 years, not once but twice, as a result of advances in endocrine therapy. In the first case, Mina and Sledge identify tamoxifen as the first targeted treatment for breast cancer. This is a reasonable assessment, as the translation work on tumor targeting ultimately was shown to be successful. Perhaps equally important was the fact that tamoxifen has a beneficial therapeutic ratio that facilitated its use as a long-term adjuvant therapy. The application of the laboratory strategy of long-term antihormonal therapy targeted to the estrogen receptor (ER)[3,4] saved lives, which in turn has contributed significantly to the national reductions in mortality.[5,6]
Secondly, the knowledge gained with tamoxifen propelled the drug forward for testing as the first chemopreventive for any cancer, created a new drug group—the selective ER modulators (SERMs)—and resurrected keoxifene, a failed breast cancer drug,to be the first SERM for the treatment and prevention of osteoporosis, but with the ability to reduce the risk of breast and endometrial cancer.
The story of the discovery of tamoxifen as a "morning after pill" in the 1960s to then being reinvented as a targeted breast cancer therapy in the 1970s has been recounted recently.[3,4]Nevertheless, the tale is important to retell, as it illustrates how changing fashions in research can influence progress. The development of the oral contraceptive by Pincus and colleagues at the Worcester Foundation during the 1950s changed society forever. Despite enthusiasm to create new ways to manipulate reproduction, the fashion of research in reproductive biology declined steadily throughout the 1960s with a decreased investment in the development of new contraceptive methods. But, in its place, the "War on Cancer" was declared in 1971.
The tale of tamoxifen also illustrates the length of time that must be taken to evaluate successful treatment strategies to effect changes in health care. Nevertheless, momentum to change the approach to the treatment of breast cancer, and, indeed, of any cancer, accelerated with tamoxifen. The drug became a ubiquitous tool to test targeting in breast cancer. More importantly, tamoxifen set the stage for the current optimism that important advances in cancer research are within our grasp and the sincere belief that clever people will solve problems and develop practical ways to kill cancer cells selectively with minimal side effects for the patient.
Although it is not possible to recapture the exact mood of the clinical community during the early 1980s, it is fair to say that chemotherapy was king. It is possible, however, to illustrate the unimportance of antihormonal therapy by reference to the work of opinion leaders at the time.
From the Bottom Looking Up
In the early 1980s, you could refer to two bibles if you wanted to know about a particular treatment or medicine. Goodman and Gilman's The Pharmacological Basis of Therapeutics (7th edition),published in 1985, is where you would go first to look up the importance of tamoxifen in medicine. The book has less than a page on the anticancer uses of tamoxifen and a short discussion of antiestrogen action relevant to the induction of ovulation. What you will find is reference to a couple of review articles that were written to consolidate all the small and scattered reports about the pharmacology, clinical studies, and future potential of antiestrogens.[9,10]
The second book—the Pharmacologic Principles of Cancer Treatment—was edited by Bruce Chabner and published in 1982. In this 443-page book, the structure of tamoxifen is shown on page 148 and descriptive information about antiestrogen therapy appears on pages 164 and 165. The absence of anything futher about the agent was not an omission. There was not much optimism about the use of tamoxifen at that time. Although a preliminary study of the efficacy of ICI 46,474 (tamoxifen) first appeared in 1971, the response rates were the same as for other endocrine therapies. The clinical development of tamoxifen to treat advanced breast cancer did not set the world on fire! Importantly, however, there were fewer side effects compared to other treatments. Tamoxifen was approved for the treatment of advanced breast cancer in the United States in December 1977, but how could the drug be used to its best advantage in the clinic?
Focus on Chemotherapy
In the early 1980s, most eyes were focused on the merits of combination chemotherapy and its value as a curative adjuvant therapy. Reference to the proceedings of a 4-day meeting reported in Adjuvant Therapy of Cancer IV, edited by Stephen Jones and Syd Salmon (1984), illustrates the quest by cooperative groups worldwide to use chemotherapy to cure cancer. Almost half of the 64 papers presented focus on the adjuvant therapy of breast cancer, with only 8 of the 26 breast cancer papers mentioning the evaluation of 1 or 2 years of tamoxifen treatment in their protocols. Away from the application of adjuvant therapy to enhance survival, the quest for cancer cure was focused on dose-dense chemotherapy and the empirical application of bone marrow transplantation. This was admirably reviewed by I. Craig Henderson in Breast Diseases.
That said, why did the process of moving from concept to changes in health care take such a long time for a novel targeted therapy with few side effects?
Dr. Jordan is supported by SPORE in Breast Cancer CA89018, R01 GM061756, The Avon Foundation, and the Weg Fund of the Fox Chase Cancer Center.
1. Mina L, Sledge GWJ: Twenty years of systemic therapy for breast cancer. Oncology (Williston Park) 20:25-32, 2006.
2. Jensen EV, Jordan VC: The estrogen receptor: A model for molecular medicine. The Dorothy P. Landon AACR Prize for Translational Research. Clin Cancer Res 9:1980-1989, 2003.
3. Jordan VC: Tamoxifen: A most unlikely pioneering medicine. Nature Reviews Drug Discovery 2:205-213, 2003.
4. Jordan VC: Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer. Br J Pharmacol 147: S269-S276, 2006.
5. Tamoxifen for early breast cancer: An overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet 354:1451-1467, 1998.
6. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet 365:1687-717, 2005.
7. Buzdar AU, Marcus C, Holmes F, et al: Phase II evaluation of Ly156758 in metastatic breast cancer. Oncology (Williston Park) 45:344-3455, 1988.
8. Cummings SR, Eckert S, Krueger KA, et al: The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 281:2189-2197, 1999.
9. Jordan VC: Biochemical pharmacology of antiestrogen action. Pharmacol Rev 36:245-276, 1984.
10. Furr BJ, Jordan VC: The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 25:127-205, 1984.
11. Cole MP, Jones CT, Todd ID: A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI 46474. Br J Cancer 25:270-275, 1971.
12. Henderson IC: Chemotherapy of advanced disease, in Harris JR, Hellman S, Henderson IC, et al (eds): Breast Diseases, pp 428-479. Philadelphia, Lippincott Company, 1987.
13. Harper MJ, Walpole AL: Mode of action of I.C.I. 46,474 in preventing implantation in rats. J Endocrinol 37:83-92, 1967.
14. Williamson JG, Ellis JP: The induction of ovulation by tamoxifen. J Obstet Gynaec Br Commonw 80:844-847, 1973.
15. Ward HW: Anti-oestrogen therapy for breast cancer: A trial of tamoxifen at two dose levels. Br Med J 1:13-14, 1973.
16. Jordan VC: The development of tamoxifen for breast cancer therapy: A tribute to the late Arthur L. Walpole. Breast Cancer Res Treat 11:197-209, 1988.
17. Tormey DC, Jordan VC: Long-term tamoxifen adjuvant therapy in node-positive breast cancer: A metabolic and pilot clinical study. Breast Cancer Res Treat 4:297-302, 1984.
18. Scottish Cancer Trials Office (MRC), Edinburgh: Adjuvant tamoxifen in the management of operable breast cancer: The Scottish trial. Report from the Breast Cancer Trials Committee. Lancet 2:171-175, 1987.
19. Fisher B, Brown A, Wolmark N, et al: Prolonging tamoxifen therapy for primary breast cancer. Findings from the National Surgical Adjuvant Breast and Bowel Project clinical trial. Ann Intern Med 106:649-654, 1987.
20. Baum M, Brinkley DM, Dossett JA, et al: Improved survival among patients treated with adjuvant tamoxifen after mastectomy for early breast cancer (letter). Lancet 2:450, 1983.
21. Controlled trial of tamoxifen as adjuvant agent in management of early breast cancer. Interim analysis at four years by Nolvadex Adjuvant Trial Organisation. Lancet 1:257-261, 1983.
22. Colletta AA, Benson JR, Baum M: Alternative mechanisms of action of anti-oestrogens. Breast Cancer Res and Treat 31:5-9, 1994.
23. Review of mortality results in randomized trials in early breast cancer. Lancet 2:1205, 1984.
24. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. Early Breast Cancer Trialists’ Collaborative Group. N Engl J Med 319:1681-1692, 1988.
25. Consensus Conference. Adjuvant chemotherapy for breast cancer. JAMA 254:3461-3463, 1985.
26. Lipton A, Santen RJ: Medical adrenalectomy using aminoglutethimide and dexamethasone in advanced breast cancer. Cancer 33:503-512, 1974.
27. Santen RJ, Wells SA: The use of aminoglutethimide in the treatment of patients with metastatic carcinoma of the breast. Cancer 46:1066-1074, 1980.
28. Harris AL: Could aminoglutethimide replace adrenalectomy. Breast Cancer Res Treat 6:201-211, 1985.
29. Brodie AMH, Wing LY, Dowsett M,
et al: Inhibitors of the aromatase enzyme system: Basic and clinical studies with 4-hydroxyandrostenedione, in Jordan VC (ed): Estrogen/Antiestrogen Action and Breast Cancer Therapy, pp 221-234. Madison, Wisc, University of Wisconsin Press, 1986.
30. Sporn MB: Approaches to prevention of epithelial cancer during the preneoplastic period. Cancer Res 36:2699-2702, 1976.
31. Muggia FM, Greenspan EM: Workshop on chemoprevention of breast cancer. Cancer Res 44:3151-3154, 1984.
32. Jordan VC: Antitumour activity of the antioestrogen ICI 46,474 (tamoxifen) in the dimethylbenzanthracene (DMBA)-induced rat mammary carcinoma model. J Steroid Biochem 5:354, 1974.
33. Jordan VC: Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA- induced rat mammary carcinoma. Eur J Cancer 12:419-424, 1976.
34. Jordan VC, Allen KE: Evaluation of the antitumour activity of the non-steroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model. Eur J Cancer 16:239-251, 1980.
35. Jordan VC, Allen KE, Dix CJ: Pharmacology of tamoxifen in laboratory animals. Cancer Treat Rep 64:745-759, 1980.
36. Powles TJ, Hardy JR, Ashley SE, et al: A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer. Br J Cancer 60:126-131, 1989.
37. Jordan VC: Tamoxifen mechanism of antitumour activity in animals and man. Proceedings of the Eastern Cooperative Oncology Group Meeting, Jasper, Alberta, June 22-25, 1974.
38. Jordan VC: Antiestrogenic and antitumor properties of tamoxifen in laboratory animals. Cancer Treat Rep 60:1409-1419, 1976.
39. Jordan VC: Use of the DMBA-induced rat mammary carcinoma system for the evaluation of tamoxifen as a potential adjuvant therapy. Reviews on Endocrine-Related Cancer October(suppl):49-55, 1978.
40. Tormey DC, Rasmussen P, Jordan VC: Long-term adjuvant tamoxifen study: clinical update. Breast Cancer Res Treat 9:157-158, 1987.
41. Tormey DC, Gray R, Falkson HC: Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. J Natl Cancer Inst 88:1828-1833, 1996.
42. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists’ Collaborative Group. Lancet 339:1-15, 1992.
43. Rose DP, Davis TE: Ovarian function in patients receiving adjuvant chemotherapy for breast cancer. Lancet 1:1174-1176, 1977.
44. Ravdin PM, Fritz NF, Tormey DC, et al: Endocrine status of premenopausal node-positive breast cancer patients following adjuvant chemotherapy and long-term tamoxifen. Cancer Res 48:1026-1029, 1988.
45. Jordan VC, Fritz NF, Langan-Fahey S, et al: Alteration of endocrine parameters in premenopausal women with breast cancer during long-term adjuvant therapy with tamoxifen as the single agent. J Natl Cancer Inst 83:1488-1491, 1991.
46. Castiglione-Gertsch M, O’Neill A, Price KN, et al: Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: A randomized trial. J Natl Cancer Inst 95:1833-46, 2003.
47. Davidson NE, O’Neill AM, Vukov AM, et al: Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: Results from INT 0101 (E5188). J Clin Oncol 23:5973-5982, 2005.
48. Beall PT, Misra KL, Young RL, et al: Clomiphene protects against osteoporosis in the mature ovariectomized rat. Calcif Tissue Int 36:123-125, 1985.
49. Jordan VC, Phelps E, Lindgren JU: Effects of anti-estrogens on bone in castrated and intact female rats. Breast Cancer Res Treat 10:31-35, 1987.
50. Turner RT, Wakley GK, Hannon KS, et al: Tamoxifen prevents the skeletal effects of ovarian hormone deficiency in rats. J Bone Miner Res 2:449-456, 1987.
51. Turner RT, Wakley GK, Hannon KS, et al: Tamoxifen inhibits osteoclast-mediated resorption of trabecular bone in ovarian hormone-deficient rats. Endocrinology 122:1146-1150, 1988.
52. Turken S, Siris E, Seldin D, et al: Effects of tamoxifen on spinal bone density in women with breast cancer. J Natl Cancer Inst 81:1086-1088, 1989.
53. Love RR, Mazess RB, Barden HS, et al: Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 326:852-856, 1992.
54. Gottardis MM, Robinson SP, Satyaswaroop PG, et al: Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res 48:812-815, 1988.
55. Hardell L: Tamoxifen as risk factor for carcinoma of corpus uterus. Lancet, 2:563, 1988.
56. Jordan VC: Tamoxifen and endometrial cancer (letter). Lancet 2:1019, 1988.
57. Fornander T, Rutqvist LE, Cedermark B, et al: Adjuvant tamoxifen in early breast cancer: Occurrence of new primary cancers. Lancet 1:117-120, 1989.
58. Neven P, DeMuylder X, Van Belle Y, et al: Tamoxifen and the uterus and endometrium (letter). Lancet 1:375, 1989.
59. Stewart HJ, Knight GM: Tamoxifen and the uterus and endometrium (letter). Lancet 1:375-376, 1989.
60. Fisher B, Costantino JP, Redmond CK, et al: Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14 (see comments). J Natl Cancer Inst 86:527-537, 1994.
61. Magriples U, Naftolin F, Schwartz PE, et al: High grade endometrial carcinoma in tamoxifen treated breast cancer patients. J Clin Oncol 11:485-490, 1993.
62. Fisher B, Costantino JP, Wickerham DL, et al: Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371-1388, 1998.
63. Fisher B, Costantino JP, Wickerham DL, et al: Tamoxifen for the prevention of breast cancer: Current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 97:1652-1662, 2005.
64. Greaves P, Goonetilleke R, Nunn G, et al: Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats. Cancer Res 53:3919-3924, 1993.
65. Gottardis MM, Jordan VC: Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res 47:4020-4024, 1987.
66. Jordan VC: Chemosuppression of breast cancer with tamoxifen: Laboratory evidence and future clinical investigations. Cancer Invest 6:589-595, 1988.
67. Lerner LJ, Jordan VC: The development of antiestrogens for the treatment of breast cancer: Eighth Cain Memorial Award Lecture. Cancer Res 50:4177-4189, 1990.
68. Black LJ, Jones CD, Falcone JF: Antagonism of estrogen action with a new benzothiophene derived antiestrogen. Life Sci 32:1031-1036, 1983.
69. Jordan VC, Gosden B: Inhibition of the uterotropic activity of estrogens and antiestrogens by the short acting antiestrogen LY117018. Endocrinology 113:463-468, 1983.
70. Gottardis MM, Ricchio ME, Satyaswaroop PG, et al: Effect of steroidal and nonsteroidal antiestrogens on the growth of a tamoxifen-stimulated human endometrial carcinoma (EnCa101) in athymic mice. Cancer Res 50:3189-3192, 1990.
71. Ettinger B, Black DM, Mitlak BH, et al: Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators (see comments) (published erratum appears in JAMA 282:2124, 1999). JAMA 282:637-645, 1999.
72. Cauley JA, Norton L, Lippman ME, et al: Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 65:125-134 2001.
73. Walsh BW, Kuller LH, Wild RA, et al: Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 279:1445-1451, 1998.
74. Jordan VC: Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents. J Med Chem 46:1081-1111, 2003.
75. Ariazi EA, Ariazi JL, Cordera F, et al: Estrogen receptors as therapeutic targets in breast cancer. Curr Top Med Chem 6:195-216, 2006.
76. Santen RJ, Worgul TJ, Samojlik E, et al: A randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer. N Engl J Med 305:545-551, 1981.
77. Coombes CR, Goss P, Dowsett M, et al: 4-hydroxyandostenedione in treatment of postmenopausal patients with advanced breast cancer. Lancet 1:1237-1239, 1984.
78. Goss PE, Ingle JN, Marino S, et al: A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349:1-10, 2003.
79. Goss PE, Ingle JN, Martino S, et al: Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97:1262-1271, 2005.
80. Coombes RC, Hall E, Gibson LJ, et al: A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081-1092, 2004.
81. Boccardo F, Rubagotti A, Puntoni M, et al: Switching to anastrozole versus continued tamoxifen treatment for early breast cancer: Preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol 23:5138-5147, 2005.
82. Baum M, Buzdar AU, Cuzick J, et al: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet 359:2131-3139, 2002.
83. Howell A, Cuzick J, Baum M, et al: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 365:60-62, 2005.
84. Thurlimann B, Keshaviah A, Coates AS, et al: A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353:2747-2757, 2005.
85. Diel IJ, Solomayer EF, Costa SD, et al: Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 339:357-363, 1998.
86. Wakeling AE, Bowler J: Steroidal pure antioestrogens. J Endocrinol 112:R7-R10, 1987.
87. Gottardis MM, Jiang SY, Jeng MH, et al: Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens. Cancer Res 49:4090-4093, 1989.
88. Wakeling AE, Dukes M, Bowler J: A potent specific pure antiestrogen with clinical potential. Cancer Res 51:3867-3873, 1991.
89. Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG, et al: Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst 87:746-750, 1995.
90. Howell A, Robertson JFR, Quaresma Albano J, et al: Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 20:3396-3403, 2002.
91. Osborne CK, Pippen J, Jones SE, et al: Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: Results of a North American trial. J Clin Oncol 20:3386-3395, 2002.
92. Pike AC, Brzozowski AM, Walton J, et al: Structural insights into the mode of action of a pure antiestrogen. Structure 9:145-153, 2001.
93. Wijayaratne AL, McDonnell DP: The human estrogen receptor-alpha is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators. J Biol Chem 276:35684-35692, 2001.
94. Jordan VC: What if tamoxifen (ICI 46,474) had been found to produce rat liver tumors in 1973? A personal perspective. Ann Oncol 6:29-34, 1995.
95. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684, 2005.
96. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al: Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354:809-820, 2006.
97. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672, 2005.
98. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987.
99. Hard GC, Iatropoulos MJ, Jordan K, et al: Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl:CD(BR) rats. Cancer Res 53:4534-4541, 1993.
100. Pagani O, Gelber S, Price K, et al: Toremifene and tamoxifen are equally effective for early-stage breast cancer: First results of International Breast Cancer Study Group Trials 12-93 and 14-93. Ann Oncol 15:1749-1759, 2004.
101. Jordan VC: Selective estrogen receptor modulation: Concept and consequences in cancer. Cancer Cell 5:207-213, 2004.
102. Yao K, Lee ES, Bentrem DJ, et al: Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice. Clin Cancer Res 6:2028-2036, 2000.
103. Lewis JS, Meeke K, Osipo C, et al: Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation. J Natl Cancer Inst 97:1746-1759, 2005.